Astellas Pharma Inc.

Astellas Pharma Inc. (Japan) holds 2 active US FDA Type II Drug Master Files and 18 inactive and has DMF or CEP filings on record for 14 active ingredients. 16 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Astellas Pharma Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/astellas-pharma-inc

Overview

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company focused on improving the health of people around the world by providing innovative and reliable pharmaceutical products. The company is engaged in the research, development, manufacturing, and marketing of prescription drugs across a wide range of therapeutic areas.

Core services & business areas

ManufacturingQuality ControlRegulatory AffairsPharmaceutical ManufacturingDrug Development

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Astellas Pharma Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Astellas Pharma Inc. holds 2 active (20 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • TACROLIMUS (FK506) DRUG SUBSTANCEActive2003-09-12
  • FK463 DRUG SUBSTANCEActive1998-02-11
  • FK1706Inactive2005-03-31
  • FK555 DRUG SUBSTANCEInactive2004-09-15
  • FK330 DRUG SUBSTANCEInactive2004-04-22
  • FK962Inactive2004-02-19
  • FK 881 DRUG SUBSTANCEInactive2003-06-27
  • FK778 DRUG SUBSTANCEInactive2001-08-06
  • CEFAZOLIN SODIUM (STERILE)Inactive1998-09-01
  • YM087 DRUG SUBSTANCEInactive1998-02-10
  • FORMOTEROL FUMARATEInactive1997-02-24
  • TAMSULOSIN HYDROCHLORIDEInactive1995-12-01
  • CEFIXIMEInactive1991-12-31
  • 7 ACA-A48Inactive1991-12-16
  • CEFAZOLINInactive1991-10-08
  • OXY-COMPOUND AN INTERMEDIATE TO PURIFIED CEFTIZOXIMEInactive1991-05-08
  • CEPHALOSPORIN (ORAL) (FK482 CEFDINIR, CI-983)Inactive1990-03-28
  • FAMOTIDINEInactive1985-03-20
  • CEFOTETANInactive1983-09-06
  • CEPHALOSPRIN C FERMENTATION AND RECOVERY IN OSAKA, JAPAN.Inactive1972-08-07

FDA compliance signals

16 FDA enforcement records linked to this company.

  • 4832025-06-06

    Validation lacking for sterile drug products

  • 4832025-06-06

    Absence of Written Procedures

  • 4832023-10-27

    Complaint Investigation/Follow-Up Findings

  • 4832019-03-05

    Investigations of discrepancies, failures

  • 4832019-03-05

    Control procedures to monitor and validate performance

  • 4832019-03-05

    Scientifically sound laboratory controls

  • 4832019-03-05

    Calibration/Inspection/Checking not done

  • 4832019-03-05

    Annual visual exams of drug products

  • 4832019-03-05

    Protective Apparel Not Worn

  • 4832019-03-05

    Written in-process control procedures

  • 4832019-03-05

    Procedures for sterile drug products

  • 4832014-04-11

    Procedures for sterile drug products

  • 4832014-04-11

    Product flow through building is inadequate

  • 4832014-04-11

    Written record of investigation incomplete

  • 4832014-04-11

    Equipment for Environmental Control

  • 4832014-04-11

    Control procedures to monitor and validate performance

For suppliers

Is this Astellas Pharma Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.